JP6860585B2 - 非環状抗ウイルス 優先出願の参照による組み込み - Google Patents

非環状抗ウイルス 優先出願の参照による組み込み Download PDF

Info

Publication number
JP6860585B2
JP6860585B2 JP2018547294A JP2018547294A JP6860585B2 JP 6860585 B2 JP6860585 B2 JP 6860585B2 JP 2018547294 A JP2018547294 A JP 2018547294A JP 2018547294 A JP2018547294 A JP 2018547294A JP 6860585 B2 JP6860585 B2 JP 6860585B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
pharmaceutically acceptable
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018547294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509288A5 (enExample
JP2019509288A (ja
Inventor
ベイゲルマン，レオニド
ワン，ガンジ
ゾン，ミンハン
Original Assignee
ヤンセン バイオファーマ インク．
ヤンセン バイオファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオファーマ インク．, ヤンセン バイオファーマ インク． filed Critical ヤンセン バイオファーマ インク．
Publication of JP2019509288A publication Critical patent/JP2019509288A/ja
Publication of JP2019509288A5 publication Critical patent/JP2019509288A5/ja
Application granted granted Critical
Publication of JP6860585B2 publication Critical patent/JP6860585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/51113—Topsheet, i.e. the permeable cover or layer facing the skin comprising an additive, e.g. lotion or odour control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/512—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/513—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its function or properties, e.g. stretchability, breathability, rewet, visual effect; having areas of different permeability
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/514—Backsheet, i.e. the impermeable cover or layer furthest from the skin
    • A61F13/51401—Backsheet, i.e. the impermeable cover or layer furthest from the skin characterised by the material
    • A61F13/51405—Backsheet, i.e. the impermeable cover or layer furthest from the skin characterised by the material treated or coated, e.g. with moisture repellent agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F2013/51002—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads with special fibres
    • A61F2013/51023—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads with special fibres being polymeric fibres
    • A61F2013/51026—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads with special fibres being polymeric fibres being in thermoplastic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018547294A 2016-03-09 2017-03-09 非環状抗ウイルス 優先出願の参照による組み込み Expired - Fee Related JP6860585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305723P 2016-03-09 2016-03-09
US62/305,723 2016-03-09
PCT/US2017/021559 WO2017156262A1 (en) 2016-03-09 2017-03-09 Acyclic antivirals

Publications (3)

Publication Number Publication Date
JP2019509288A JP2019509288A (ja) 2019-04-04
JP2019509288A5 JP2019509288A5 (enExample) 2020-04-16
JP6860585B2 true JP6860585B2 (ja) 2021-04-14

Family

ID=58361178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547294A Expired - Fee Related JP6860585B2 (ja) 2016-03-09 2017-03-09 非環状抗ウイルス 優先出願の参照による組み込み

Country Status (7)

Country Link
US (2) US10745427B2 (enExample)
EP (1) EP3426642A4 (enExample)
JP (1) JP6860585B2 (enExample)
CN (1) CN109071467B (enExample)
AU (1) AU2017231824B2 (enExample)
TW (1) TWI740910B (enExample)
WO (1) WO2017156262A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10745427B2 (en) 2016-03-09 2020-08-18 Janssen Biopharma, Inc. Acyclic antivirals
EP3515923A1 (en) * 2016-09-23 2019-07-31 Katholieke Universiteit Leuven Prodrugs of fluorinated acyclic nucleoside phosphonates
CN111615391B (zh) * 2018-01-19 2023-05-30 吉利德科学公司 比卡格韦的代谢物
BR112021010351A2 (pt) 2018-12-12 2021-08-31 Janssen Biopharma, Inc. Análogos de ciclopentil nucleosídeos como antivirais
MX2021006992A (es) 2018-12-12 2021-11-17 Janssen Biopharma Inc Análogos de nucleósidos de ciclobutilo como antivirales.
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
JP2023500794A (ja) 2019-10-17 2023-01-11 エーアイ‐バイオファーマ 抗ウイルス薬および肝臓標的薬
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
CN111909153B (zh) * 2020-04-16 2021-11-19 山东鲁西药业有限公司 7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的合成工艺
EP4161557B1 (en) * 2020-06-04 2026-03-11 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Ws-635 for use in the treatment or prevention of sars-cov-2 infection
WO2022081823A1 (en) * 2020-10-14 2022-04-21 Temple University -Of The Commonwealth System Of Higher Education Pharmacologic approach for suppression of coronaviruses
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US5877166A (en) * 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE19912636A1 (de) * 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
EA200400690A1 (ru) * 2001-11-14 2005-06-30 Байокрист Фармасьютикалз, Инк. Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
FR2850653A1 (fr) * 2003-02-04 2004-08-06 Univ Pasteur Derives de pyrazolotriazine, procede de preparation et utilisations
EP1620109A2 (en) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
CN1819832A (zh) * 2003-04-25 2006-08-16 吉里德科学公司 激酶抑制性膦酸酯类似物
US20050080053A1 (en) * 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
TW200533358A (en) * 2004-02-17 2005-10-16 Anadys Pharmaceuticals Inc Nucleoside phosphonate derivatives useful in the treatment of hiv infections
PT2258376T (pt) * 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
NZ598927A (en) * 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
CN101066981B (zh) * 2007-05-25 2011-10-05 中国科学院上海药物研究所 非环核苷膦酸酯类化合物及其组合物、制备方法和用途
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
PL2280973T3 (pl) 2008-04-23 2013-05-31 Gilead Sciences Inc Analogi karba-nukleozydowe do leczenia przeciwwirusowego
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
DK2480552T3 (en) * 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
JP6338402B2 (ja) 2014-03-07 2018-06-06 日東電工株式会社 樹脂フィルム
US10745427B2 (en) 2016-03-09 2020-08-18 Janssen Biopharma, Inc. Acyclic antivirals

Also Published As

Publication number Publication date
US20190055273A1 (en) 2019-02-21
US10745427B2 (en) 2020-08-18
EP3426642A1 (en) 2019-01-16
CN109071467A (zh) 2018-12-21
US20200392169A1 (en) 2020-12-17
WO2017156262A1 (en) 2017-09-14
TW201741314A (zh) 2017-12-01
AU2017231824B2 (en) 2021-07-01
AU2017231824A1 (en) 2018-09-27
JP2019509288A (ja) 2019-04-04
CN109071467B (zh) 2023-04-04
EP3426642A4 (en) 2019-10-09
US11472826B2 (en) 2022-10-18
TWI740910B (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
US11472826B2 (en) Acyclic antivirals
ES2623794T3 (es) Intermedios para la preparación de moduladores de receptores tipo toll
CN103827130B (zh) 2′‑氟‑6′‑亚甲基碳环核苷和治疗病毒感染的方法
DK2794629T3 (en) 2 ', 4'-DIFLUOR-2'-METHYL-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
CN102256991B (zh) 尿嘧啶基环丙基核苷酸
AU2018212788A1 (en) Cyclic dinucleotides as STING agonists
TW201429983A (zh) 經取代之核苷、核苷酸及其類似物
JP2015517975A (ja) フラビウイルス感染の処置のためのスピロ［２．４］ヘプタン
TW201919649A (zh) 作為ｈｃｖ ｒｎａ複製抑制劑之經４′－氟－２′－甲基取代之核苷衍生物
CN114867351A (zh) 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
US20220033406A1 (en) Cyclopentyl nucleoside analogs as anti-virals
US20240279227A1 (en) Fused heterocyclic derivatives
US20220048912A1 (en) Cyclobutyl nucleoside analogs as anti-virals
CN107531739A (zh) 作为用于治疗丙型肝炎的hcv抑制剂的核苷酸衍生物
ES2993261T3 (en) Spirocyclic inhibitors of hepatitis b virus
HK1194385A (en) 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210326

R150 Certificate of patent or registration of utility model

Ref document number: 6860585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees